Earnings Report Card, Q1/12, Regenerative Medicine Universe – So far
An earnings release is a ‘report card’ of sorts for a public stem cell company. The current LPS (loss per share) standings reflect the universes’ investing status. By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity of stem cell research and whether or not it deserves their investment.
Geron (GERN): http://www.scimitarequity.com/upload/GERN307282.pdf
Dendreon (DNDN): http://www.scimitarequity.com/upload/DNDN%20Q1%20Results229879.pdf